Pacira BioSciences (PCRX) financial statements
Pacira BioSciences reported revenue of $726M in fiscal 2025, up 11.3% a year over 9 years.
Net income was $7M and the operating margin 2.6%, against -11.6% in 2016.
Free cash flow was $137M, and the company returned $148M in net buybacks.
The diluted share count rose 21% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Pacira BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $276M | $287M | $337M | $421M | $430M | $542M | $667M | $675M | $701M | $726M |
| Cost of revenue | $110M | $88M | $87M | $107M | $117M | $140M | $199M | $185M | $170M | $150M |
| Gross profit | $166M | $199M | $250M | $314M | $312M | $401M | $468M | $490M | $531M | $577M |
| Research and development | $46M | $57M | $56M | $72M | $59M | $56M | $85M | $76M | $82M | $117M |
| Selling, general and admin | $153M | $161M | $177M | $201M | $194M | $199M | $255M | $269M | $294M | $369M |
| Operating income | -$32M | -$25M | $16M | $10M | $46M | $90M | $60M | $88M | -$73M | $19M |
| Interest expense | $7M | $18M | $22M | $24M | $26M | $32M | $40M | $20M | $17M | $17M |
| Pre-tax income | -$38M | -$42M | -$425,000 | -$11M | $20M | $56M | $13M | $62M | -$63M | $17M |
| Income tax | $105,000 | $140,000 | $46,000 | $268,000 | -$125M | $14M | -$3M | $20M | $36M | $10M |
| Net income | -$38M | -$43M | -$471,000 | -$11M | $146M | $42M | $16M | $42M | -$100M | $7M |
| EPS (diluted) | -$1.02 | -$1.07 | -$0.01 | -$0.27 | $3.33 | $0.92 | $0.34 | $0.89 | -$2.15 | $0.16 |
| Diluted shares | 37M | 40M | 41M | 42M | 44M | 46M | 47M | 52M | 46M | 45M |
| Gross margin | 60.2% | 69.3% | 74.3% | 74.7% | 72.7% | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| Operating margin | -11.6% | -8.7% | 4.7% | 2.5% | 10.8% | 16.6% | 9.0% | 13.0% | -10.5% | 2.6% |
| Net margin | -13.7% | -14.9% | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
Balance sheet
Fiscal years, from Pacira BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $173M | $311M | $383M | $292M | $522M | $656M | $289M | $279M | $485M | $238M |
| Receivables | $30M | $32M | $38M | $48M | $53M | $96M | $98M | $106M | $113M | $124M |
| Inventory | $31M | $41M | $49M | $58M | $65M | $99M | $96M | $104M | $125M | $153M |
| Total current assets | $243M | $391M | $478M | $409M | $652M | $866M | $498M | $510M | $745M | $548M |
| Property, plant and equipment | $101M | $107M | $109M | $105M | $137M | $188M | $184M | $174M | $167M | $141M |
| Goodwill | $47M | $55M | $62M | $100M | $100M | $145M | $163M | $163M | $0 | $20M |
| Total assets | $391M | $628M | $689M | $831M | $1.3B | $2.1B | $1.7B | $1.6B | $1.6B | $1.3B |
| Total current liabilities | $45M | $56M | $61M | $108M | $253M | $521M | $148M | $97M | $310M | $121M |
| Long-term debt | — | — | — | — | — | — | — | — | $384M | $372M |
| Total liabilities | $172M | $349M | $368M | $476M | $655M | $1.3B | $906M | $704M | $775M | $572M |
| Shareholders' equity | $219M | $279M | $321M | $355M | $620M | $730M | $775M | $870M | $778M | $693M |
| Net debt | $83M | -$54M | -$133M | -$78M | -$100M | -$586M | -$104M | -$153M | $309M | $214M |
Cash flow
Fiscal years, from Pacira BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33M | $18M | $49M | $71M | $77M | $126M | $145M | $155M | $189M | $152M |
| Capital spending | $25M | $19M | $15M | $10M | $38M | $46M | $30M | $15M | $11M | $15M |
| Free cash flow | $9M | -$1M | $34M | $60M | $39M | $80M | $115M | $139M | $179M | $137M |
| Stock-based compensation | $31M | $32M | $32M | $34M | $40M | $42M | $48M | $48M | $51M | $58M |
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | -$25M | -$148M |
| Net borrowing | -$4,000 | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 3.2% | -0.5% | 10.2% | 14.3% | 9.1% | 14.7% | 17.3% | 20.7% | 25.5% | 18.8% |
Questions
What was Pacira BioSciences's revenue in 2025?
$726M in fiscal 2025, from its 10-K filing.
How much free cash flow does Pacira BioSciences generate?
$137M in fiscal 2025 (operating cash flow minus capital spending).
From Pacira BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.